Daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
From the U.S. FDA-approved label for Daunorubicin. Full label: DailyMed.
Daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
From the U.S. FDA-approved label for Daunorubicin. Full label: DailyMed.
Parenteral drug products should be inspected visually for particulate matter prior to administration, whenever solution and container permit. Principles In order to eradicate the leukemic cells and induce a complete remission, a profound suppression of the bone marrow is usually required. Evaluation of both the peripheral blood and bone marrow is mandatory in the formulation of appropriate treatment plans.
Directions from the U.S. FDA-approved label — your doctor or pharmacist may advise differently.
Daunorubicin hydrochloride injection is contraindicated in patients who have shown a hypersensitivity to it.
Excerpt from the U.S. FDA-approved label. Talk to a pharmacist or doctor before use.
Bone Marrow Daunorubicin hydrochloride is a potent bone marrow suppressant. Suppression will occur in all patients given a therapeutic dose of this drug. Therapy with daunorubicin hydrochloride should not be started in patients with pre-existing drug-induced bone marrow suppression unless the benefit from such treatment warrants the risk. Persistent, severe myelosuppression may result in superinfection or hemorrhage. Cardiac Effects Special attention must be given to the potential cardiac toxicity of daunorubicin hydrochloride, particularly in infants and children.
Warnings and precautions excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor before use.
Dose-limiting toxicity includes myelosuppression and cardiotoxicity (see WARNINGS section). Other reactions include: Cutaneous Reversible alopecia occurs in most patients. Rash, contact dermatitis and urticaria have occurred rarely. Gastrointestinal Acute nausea and vomiting occur but are usually mild. Antiemetic therapy may be of some help. Mucositis may occur 3 to 7 days after administration.
Excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor about side effects.
6 products from 6 makers in the NepalDoc medicine catalog use this generic:
| Brand | Composition | Maker | Pack |
|---|---|---|---|
| Aunomycin 20mg Injection | Daunorubicin (20mg) | Pharmaco | |
| Daunotec 20mg Injection | Daunorubicin (20mg) | Cipla Ltd. | |
| Dauneon 20mg Injection | Daunorubicin (20mg) | Neon Laboratories Ltd | vial of 1 ml Injection |
| Daunocin 20mg Injection | Daunorubicin (20mg) | Vhb Life Sciences Inc | vial of 2 ml Injection |
| Daunomycin 20mg Injection | Daunorubicin (20mg) | Pfizer Ltd | vial of 10 ml Injection |
| Daunorubitec Injection | Daunorubicin (20mg) | United Biotech Pvt Ltd | vial of 1 Injection |
Brand list from the NepalDoc medicine catalog. Availability varies by pharmacy — call ahead to confirm stock.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. NLEM listing does not guarantee that a medicine is in stock at any pharmacy.
